Literature DB >> 11236898

Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients.

M Meisner1, E Hüttemann, T Lohs, L Kasakov, K Reinhart.   

Abstract

We determined the elimination characteristics of procalcitonin (PCT) during continuous veno-venous hemofiltration (CVVHF) and the resulting effect on PCT plasma levels. A prospective study was conducted in patients with sepsis and acute oliguric renal failure, treated with CVVHF using a polysulfone membrane (Baxter Renaflo II PSHF 1200). Patients had sepsis and PCT plasma levels > 4 ng ml(-1) (n = 26). PCT was measured in the pre- and post-filter plasma and the ultrafiltrate at 0, 5, 10, and 15 min and 1, 2, 4, 6, 12, and 24 h after setup of CVVHF. PCT sieving coefficient was 0.24. Elimination of PCT, however, depended on the duration of filtration, because filter adsorption was the main mechanism of PCT clearance during the first hour of hemofiltration, finally increasing to a clearance of PCT into the ultrafiltrate of 2.8-5.5 mL/min after 2 h. PCT plasma levels were not significantly altered during CVVHF (96% of the initial concentration after 24 h, P = 0.72). Similar to what has been observed with cytokines and other proteins of a comparable molecular weight, PCT is removed from the plasma during CVVHF, but plasma PCT levels are unchanged. Thus, PCT can be used as a diagnostic parameter even in patients with acute renal failure undergoing CVVHF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236898     DOI: 10.1097/00024382-200115030-00002

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  14 in total

1.  Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients.

Authors:  Raluca Dumea; Dimitrie Siriopol; Simona Hogas; Irina Mititiuc; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2013-08-30       Impact factor: 2.370

2.  Predictive value of procalcitonin for diagnosis of infections in patients with chronic kidney disease: a comparison with traditional inflammatory markers C-reactive protein, white blood cell count, and neutrophil percentage.

Authors:  Yanbei Sun; Lijuan Jiang; Xiaonan Shao
Journal:  Int Urol Nephrol       Date:  2017-09-27       Impact factor: 2.370

Review 3.  Procalcitonin-guided antibiotic treatment in critically ill patients.

Authors:  Andreas Hohn; Bernhard Heising; Jan-Karl Schütte; Olaf Schroeder; Stefan Schröder
Journal:  Langenbecks Arch Surg       Date:  2016-06-10       Impact factor: 3.445

4.  Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock.

Authors:  Alexander Geppert; Angela Steiner; Georg Delle-Karth; Gottfried Heinz; Kurt Huber
Journal:  Intensive Care Med       Date:  2003-06-20       Impact factor: 17.440

Review 5.  Role of biomarkers in sepsis care.

Authors:  Ravi S Samraj; Basilia Zingarelli; Hector R Wong
Journal:  Shock       Date:  2013-11       Impact factor: 3.454

6.  Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis.

Authors:  Ashraf A Dahaba; Peter H Rehak; Werner F List
Journal:  Intensive Care Med       Date:  2003-03-22       Impact factor: 17.440

7.  Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac surgery.

Authors:  Dong Zhao; Jianxin Zhou; Go Haraguchi; Hirokuni Arai; Chieko Mitaka
Journal:  J Intensive Care       Date:  2014-06-03

Review 8.  Update on procalcitonin measurements.

Authors:  Michael Meisner
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

9.  Measurements in the intensive care unit: what do they mean?

Authors:  John C Marshall
Journal:  Crit Care       Date:  2003-11-11       Impact factor: 9.097

10.  Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure.

Authors:  Claude Level; Philippe Chauveau; Olivier Guisset; Marie Cécile Cazin; Catherine Lasseur; Claude Gabinsky; Stéphane Winnock; Danièle Montaudon; Régis Bedry; Caroline Nouts; Odile Pillet; Georges Gbikpi Benissan; Jean Claude Favarel-Guarrigues; Yves Castaing
Journal:  Crit Care       Date:  2003-10-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.